Floreotech
4 known investors
Floreo builds a library of immersive VR lessons designed to help develop social and behavioral regulation skills. Through its Floreo SkillsXP platform, families, therapists, and educators create individualized learning programs for use in and out of clinical settings.
Also known as Floreo Β· Floreo Inc. Β· Floreo VR
Investors Β· 4
Company profile
researched Aug 2026Floreo (operating at floreotech.com, also referenced as Floreo Inc. and Floreo VR) develops a virtual reality platform that teaches social, communication, emotional regulation, behavioral and life skills to neurodiverse individuals, initially focused on people with autism spectrum disorder (ASD). Learners wear a VR headset β an iPhone with a compatible Google Cardboard viewer, a Meta Quest 2/3/Pro, or a PICO Business headset (G3, Neo 3/Neo 3 Pro Enterprise, PICO 4E, PICO 4 Ultra) β while the lesson view is streamed in real time to a paired browser-based "coaching device." A co-pilot mode lets the supervising adult direct the lesson, see the learner's field of view, and receive suggested coaching language and prompts, as well as track progress.
The lesson library, marketed as Floreo SkillsXP, covers foundational social and communication targets (joint attention, imitation, recognizing facial expressions, orienting to communication partners, greetings, group conversation, workplace communication, decision making), independence and community-safety scenarios (responding to police questions, riding the bus, crossing streets, airport security, grocery shopping, job skills such as time management and teamwork), and emotional-regulation environments (guided underwater meditation, relaxation in a crystal cave, yoga, flight over snowy landscapes, playing a marimba). Content is described as based on established, evidence-based techniques and is developed by clinicians, therapists, engineers and neurodiverse contributors; named clinical leadership includes a VP of Clinical Operations and Quality, a VP of Clinical Product, and a Director of Therapy Content who is a BCBA.
Floreo positions itself as building a "behavioral therapy metaverse," and states an intent to extend beyond ASD to other areas of mental health such as ADHD and anxiety. The company has received the U.S. Food and Drug Administration's breakthrough device designation and has been accepted into the FDA's Total Product Life Cycle Advisory Program (TAP).
Founding story
Founder and CEO Vijay Ravindran, a co-founder of the company and the father of a child on the autism spectrum, founded Floreo in 2016 after observing first-hand the difficulties children with ASD face in learning social and executive functioning skills and how a child could respond positively to virtual reality as a tool for developing those skills. He developed a beta concept while VR was still relatively nascent, based on a belief that VR could bridge virtual and physical environments and support a vision of a world accessible to neurodiverse people.
Business model
Floreo sells its VR software on a subscription basis to therapy providers, schools and education agencies, and families, with sales handled via consultations with its team rather than app-store download. Hardware can be bundled through equipment rental options for customers lacking a compatible device. The company also pursues public reimbursement channels, positioning subscriptions as fundable through Medicaid-based programs and waivers.
Subscription pricing starts at $69.99 per month for software only for a single learner, offered on monthly or annual terms; equipment rental can be bundled into a subscription. Floreo has also drawn on non-dilutive government research funding, including NIH/NIMH Small Business Technology Transfer (STTR) support for development and testing.
Traction
In 2021 Floreo delivered more than 17,000 lessons to neurodiverse individuals across 19 countries. The platform is used by schools, therapy practices, medical practitioners and parents; The Learning Spectrum in Ohio deployed Floreo across three locations and renewed its annual subscription. Research output includes a first study on eye contact published in JMIR Pediatrics and Parenting, a 2017 Node.Health award for top evidence-based pilot, and about half a dozen papers and presentations from the Children's Hospital of Philadelphia collaboration, which reached Phase II of its NIH-funded study by early 2022.
Latest developments
Floreo has received FDA breakthrough device designation and has been accepted into the FDA's Total Product Life Cycle Advisory Program (TAP), which provides insights and resources toward commercialization. The product is marketed as Floreo SkillsXP and supports newer hardware including Meta Quest 3 and PICO 4 Ultra headsets.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Floreo presents itself as aiming to be the leading platform for developing learning content for people with developmental delays, differentiating on clinical evidence in a category where many available technology tools for ASD support have not been validated in clinical studies. It cites cost-effectiveness and scalability relative to intensive behavioral interventions, which are expensive and inconsistently delivered. Coverage includes a New York Times article on VR for autistic children, and the company is listed as a health and wellness member organization of the International Virtual Reality Healthcare Association.
Research-based content validated through peer-reviewed studies and NIH-funded work with the Center for Autism Research at Children's Hospital of Philadelphia; FDA breakthrough device designation and TAP acceptance; a coach co-pilot mode enabling supervising adults to direct and monitor sessions and track progress; support for low-cost, widely available hardware including smartphone-based VR; telehealth readiness; and content authored by clinicians, educators, disability and neurodiversity experts and neurodiverse contributors.
Technology
A VR application paired with a browser-based coaching console. The learner's headset streams the lesson view in real time to the coach's internet-connected device (Safari, Chrome, Edge or Firefox), where a co-pilot mode allows the adult to steer the lesson, view field-of-view indicators and deliver prompts and feedback. Supported learner hardware includes iPhone 7 or later on iOS 15+ with a compatible Google Cardboard viewer, Meta Quest 2/3/Pro, and PICO Business headsets; Android phones and high-end tethered consoles such as HTC Vive, Oculus Rift and PlayStation VR are not supported. The product carries FDA breakthrough device designation and TAP acceptance.
Go-to-market
Direct sales through consultation requests and a sales team, supported by a "Floreo Locator" directory of organizations using the product, testimonials from clinicians, teachers and parents, webinars and information sessions for state programs, a newsletter and blog, and training videos and knowledge base resources. The company also works with reimbursement and grant pathways (for example the Wisconsin Children's Long-Term Supports Waiver, New York OPWDD Self Directed Services Waiver as an approved CFS vendor, and Texas autism grant funding for local education agencies) and with partner organizations such as JFFLabs.
Neurodiverse individuals of any age and ability, initially those with autism spectrum disorder and related diagnoses, reached through three buyer groups: therapy practices and clinical providers (including telehealth), schools, districts and special education programs, and families/parents at home.
Geography
U.S.-based, with an address at 2 Wisconsin Circle, Suite 700, Chevy Chase, Maryland, and a Washington, DC location cited by NIMH. Lessons were delivered to learners in 19 countries in 2021, and reimbursement and program activity is noted in Maryland, Wisconsin, Washington DC, New York, Ohio and Texas.
History
Founded in 2016, Floreo published its first research study β focused on improving eye contact β in JMIR Pediatrics and Parenting; the study won the Node.Health award for top evidence-based pilot in 2017. Research at the Center for Autism Research at Children's Hospital of Philadelphia, supported by a National Institutes of Health grant, yielded roughly half a dozen papers and academic presentations. The company worked with JFFLabs (Jobs for the Future) as an impact partner from 2020 on market awareness, product fit and revenue diversification. In 2021 it secured investments from the Autism Impact Fund, Divergent Investments and the Disability Opportunity Fund, and by early 2022 was in Phase II of its NIH-funded study with Children's Hospital of Philadelphia. The company has since received FDA breakthrough device designation and acceptance into the FDA's TAP program.
Risks & controversies
The product is a supplementary learning and therapy modality rather than a standalone treatment, and its FDA pathway remains in progress: breakthrough device designation streamlines but does not complete premarket approval. Distribution depends on third-party VR hardware and is limited to iOS and specific Meta Quest and PICO headsets, with no Android support. Registration restrictions apply to children (under 10 through its services generally, and under 13 on Meta Quest headsets), and a meaningful portion of demand depends on Medicaid waivers, grants and other public funding programs that vary by state.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Non-dilutive funding Β· 2 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $289K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Timeline Β· 6
launches, deals, and filingsFloreo reports receiving the FDA's breakthrough device designation for Floreo VR and acceptance into the FDA's Total Product Life Cycle Advisory Program (TAP).
Floreo entered Phase II of its NIH-funded research study with the Center for Autism Research at Children's Hospital of Philadelphia, with further results expected in 2022.
Floreo stated it is an approved CFS vendor for the New York OPWDD Self Directed Services Waiver, allowing families to fund subscriptions with those benefits.
Floreo stated it secured investments during the prior year from the Autism Impact Fund, Divergent Investments and the Disability Opportunity Fund; no amount was disclosed.
Floreo worked with JFFLabs, the innovation lab of Jobs for the Future, on market awareness, product fit and a strategic action plan to build enterprise partner relationships and diversify revenue.
Floreo's first research study, on improving eye contact and published in JMIR Pediatrics and Parenting, won the Node.Health award for top evidence-based pilot.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- Floreotechfloreotech.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Floreotech do?
- Floreo is a virtual reality therapy platform teaching social, communication, behavioral and life skills to neurodiverse learners.
- Who are Floreotech's investors?
- Floreotech's investors include City Light, Colopl Next, Lifeforce Capital, Presence Capital.